BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Cornell University

Headquarters: Ithaca, NY, United States
Year Founded: 1865
Status: Non-biopharma

Biopharma related deals can be found by searching the organization's name in the Deals Module.

BioCentury | Apr 11, 2025
Discovery & Translation

Base editor efficiency boom. China leading charge?

Recently published studies reveal advances in precision and performance, driven largely by labs in China
BioCentury | Apr 5, 2025
Discovery & Translation

Science Spotlight: A FOXP3 regulator to enhance induced Tregs

BioCentury’s roundup of translational innovations also includes insights into high-fat diet disruption of feeding motivation; ER-targeted antigens; and more
BioCentury | Feb 15, 2025
Discovery & Translation

Science Spotlight: Using HIV to help allogeneic CAR T cells evade immune attack

BioCentury’s roundup of translational innovations also includes a human hypothalamus atlas from Novo and collaborators, and four papers with links to newcos
BioCentury | Jul 18, 2024
Discovery & Translation

Science Spotlight: Preventing NK cells from rejecting allogeneic therapies, and more

BioCentury’s roundup of translational innovations
BioCentury | May 31, 2024
Distillery Therapeutics

Inhibiting TRIM29 for viral myocarditis

BioCentury | Feb 24, 2024
Discovery & Translation

Science spotlight: New class of molecular glues, gene therapy for FTD/ALS and more

BioCentury’s roundup of translational innovations
BioCentury | May 24, 2023
Product Development

Lupus consortium could be model for joining FDA, NIH, patients and industry

ARPA-H seeking ideas for collaboration with FDA
BioCentury | May 24, 2023
Finance

May 23 Quick Takes: VCs back cancer play Larkspur with $35.5M

Plus: PTC reports vatiquinone Phase III miss, discontinuation of gene therapies and updates from Innoviva, Pfizer, Wave, Arrowhead, Icosavax and more
BioCentury | Mar 16, 2023
Data Byte

Translational spotlight on variant-proofing tech for COVID and beyond

Host targets and antiviral strategies with efficacy across multiple viruses in BioCentury’s Distillery
BioCentury | Mar 7, 2023
Deals

Amgen deal, $60M round allow Volastra to advance pair of KIF18A products

Licensing deal gives biotech clinical molecule that is more than a year ahead of its former lead synthetic lethality program
Items per page:
1 - 10 of 186